Sentence examples for primary pneumonia from inspiring English sources

Human patients with highly pathogenic avian influenza H5N1 virus typically develop a viral primary pneumonia progressing rapidly to acute respiratory distress syndrome (Abdel-Ghafar et al. 2008).

In addition to its role in flea-borne transmission, Pla on plasmid pPCP1 has been shown to contribute to the pathogenesis of bubonic and primary pneumonia plague [33] [36].

Using U.S. National Hospital Discharge Survey and WHO laboratory data during 1979 2001, Thompson and colleagues estimated that influenza was associated with 8.6% of all primary pneumonia and influenza hospitalizations and the average annual incidence across all age groups was 36.8 per 100,000 (range; 7.8 69.5)[31].

ICU patients in Mexico [ 2] mainly presented with viral primary pneumonia and mortality was extremely high.

However, a small number of individuals can develop primary pneumonia, which can progress to ARDS [ 5].

Subsequent analyses were performed as for the primary pneumonia model described above.

We developed a computer-based state-transition model that simulates the natural history of pneumonias (both primary endpoint pneumonia as defined by WHO [ 25, 26] and non-primary endpoint pneumonia) and serious clinical forms of pneumococcal diseases in order to evaluate the cost-effectiveness of routine vaccination with PCVs, compared to no vaccination from the societal perspective.

Occasionally, influenza can cause severe illness including primary viral pneumonia or secondary bacterial pneumonia.

In addition these studies provide a springboard for future analyses of more severe complications of viral influenza, including primary influenza pneumonia and secondary bacterial pneumonia [23].

Vaccinating a cohort of 60,000 infants, assuming 90% coverage, would be expected to prevent about 1400 cases (~28%) of primary endpoint pneumonia attributable to S. pneumoniae and avert hospitalization and outpatient visits due to primary endpoint pneumonia by approximately 740 and 660 cases, respectively.

Third, we follow the recent WHO standards [ 25, 26] in distinguishing all-cause pneumonias, and assume 35% efficacy against primary endpoint pneumonia while also assuming a 1.5% increase in non-primary endpoint pneumonia, based on our interpretation of trial results [ 9].